Form 8-K - Current report:
SEC Accession No. 0001493152-24-033753
Filing Date
2024-08-23
Accepted
2024-08-23 17:00:30
Documents
14
Period of Report
2024-08-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39865
  Complete submission text file 0001493152-24-033753.txt   257780

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bct-20240822.xsd EX-101.SCH 3744
3 XBRL DEFINITION FILE bct-20240822_def.xml EX-101.DEF 26582
4 XBRL LABEL FILE bct-20240822_lab.xml EX-101.LAB 36619
5 XBRL PRESENTATION FILE bct-20240822_pre.xml EX-101.PRE 25206
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5704
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 241237080
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)